Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company focused on developing innovative therapies for cardiovascular and metabolic diseases. The company is known for its work on treatments for non-alcoholic steatohepatitis (NASH), a liver disease with significant unmet medical needs. Madrigal competes with other pharmaceutical companies in the NASH treatment space, such as Intercept Pharmaceuticals and Gilead Sciences.
On January 14, 2026, Andrea Tan from Goldman Sachs set a price target of $571 for MDGL. At the time, the stock was priced at $493.90, suggesting a potential upside of 15.61%. This optimistic outlook may be influenced by Madrigal's recent participation in the 44th Annual J.P. Morgan Healthcare Conference, a key event for healthcare companies to showcase their developments and strategies.
During the conference, Madrigal likely shared updates and future plans that could impact its stock performance. Despite the current stock price of $493.90, the company has experienced a 3.26% decrease today, equating to a $16.63 drop. The day's trading range has seen a low of $493.19 and a high of $514.36, reflecting some volatility in the stock.
Over the past year, MDGL has reached a high of $615 and a low of $265, indicating significant fluctuations in its stock price. The company's market capitalization is approximately $10.95 billion, with a trading volume of 430,259 shares. These figures highlight the company's substantial presence in the market and investor interest in its potential growth.
